Skip to main content

Fiscal Wizard · Single-issue tearsheet

LIVN / Jun 21, 2026 Run #7409

LIVN

LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Composite verdict

D 42.9 / 100
Gated stand-aside 0 drivers · 6 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 25th of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: range

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -66%
Asset value $21.84Earnings power value $36.58Price $78.50

Priced above its no-growth earnings power value ($36.58/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

42.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
FCF Margin 76
Margin of Safety 0
Gross Margin 75
EPS Growth (YoY) 0
EV/Sales 75
Cash Conversion Cycle 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

6 blocking 4 caution

6 guards active, 43 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LIVN.